دراسة حول النانوزيمات كمثبطات للأصناف الأوكسجينية الفعالة لدى مرضى القلب والأوعية الدموية

Rp-A Study of Nanoenzymes as Reactive Oxygen Species Inhibition in Cardiovascular Patients.pdf

Cardiovascular diseases such as atherosclerosis, myocardial infarction, and the resulting chronic heart disease, such as heart failure, are the leading causes of death in heart illness. The role of reactive oxygen species in hypertension and atherosclerosis by lipid peroxidation and plaque formation appears clear. Here, iron oxides@Prussian Blue MNPs have gained increasing research interest. Magnetic nanoparticles have been reported to be used to adhere infections to their surface and to purify blood by magnetic separation. The aim of this study is to investigate the ability of magnetic nanoparticles to reactive oxygen species by applying external magnetic fields and to provide an innovative strategy for the treatment of diseases associated with reactive oxygen species in patients with ischemic heart disease. In this study, eighty samples were collected from male patients aged between (40 –70). These patients were diagnosed with ischemic heart disease, where 40 samples were collected from angina pectoris patients from the emergency centre of Al-Hussein Hospital. These patients were diagnosed with the disease by a specialist doctor, and 40 samples were collected from patients with ST-Elevation Myocardial Infarction from the heart coronary care unit located at Al-Hussein Teaching Hospital. And then iron oxides@Prussian blue MNPs were prepared by Co-precipitation method. The synthesis of Fe3O4@PB nanocomposites has been characterized using various techniques, including scanning electron microscopy (SEM) for morphological analysis, along with dynamic light scattering (DLS), UV−Vis-NIR spectroscopy, Fourier transform infrared spectroscopy (FT-IR), BET (brunauer-emmett-teller), X-ray diffraction (XRD) and zeta potential measurements. The results indicated a significant difference between the patient group and the control group in both IL-6 (p-value < 0.008) and TNF-alpha (p-value < 0.001). Our findings also showed significant differences in troponin concentrations among the study groups with (p-value < 0.001). The findings indicated an increase in the overall antioxidant capacity of both SOD, with a (p-value < 0.008), and GPx, with a (p-value < 0.288). Additionally, oxidative stress in patients was elevated, as evidenced by Malondialdehyde concentrations (p-value < 0.001). The rate of reduction in malondialdehyde concentrations across the two patient groups and healthy controls exhibited variability, however remained comparable. We observed that higher concentrations of iron oxide coated with Prussian blue nanoparticles corresponded with a more significant reduction in malondialdehyde levels. The two-hour incubation time resulted in a more significant reduction in malondialdehyde concentrations than the one-hour incubation period. A one-hour incubation led to a more significant reduction in malondialdehyde concentrations than a half-hour incubation. The nanoparticles we synthesized showed a decrease in malondialdehyde concentrations in both the patient group and the control group.